Transient receptor potential vanilloid 1: A potential therapeutic target for the treatment of osteoarthritis and rheumatoid arthritis.
Zhidong LiaoMuhammad UmarXingyun HuangLing QinGuozhi XiaoYan ChenLiping TongDi ChenPublished in: Cell proliferation (2023)
This study aims to determine the molecular mechanisms and analgesic effects of transient receptor potential vanilloid 1 (TRPV1) in the treatments of osteoarthritis (OA) and rheumatoid arthritis (RA). We summarize and analyse current studies regarding the biological functions and mechanisms of TRPV1 in arthritis. We search and analyse the related literature in Google Scholar, Web of Science and PubMed databases from inception to September 2023 through the multi-combination of keywords like 'TRPV1', 'ion channel', 'osteoarthritis', 'rheumatoid arthritis' and 'pain'. TRPV1 plays a crucial role in regulating downstream gene expression and maintaining cellular function and homeostasis, especially in chondrocytes, synovial fibroblasts, macrophages and osteoclasts. In addition, TRPV1 is located in sensory nerve endings and plays an important role in nerve sensitization, defunctionalization or central sensitization. TRPV1 is a non-selective cation channel protein. Extensive evidence in recent years has established the significant involvement of TRPV1 in the development of arthritis pain and inflammation, positioning it as a promising therapeutic target for arthritis. TRPV1 likely represents a feasible therapeutic target for the treatment of OA and RA.
Keyphrases
- rheumatoid arthritis
- neuropathic pain
- disease activity
- gene expression
- spinal cord
- spinal cord injury
- interstitial lung disease
- ankylosing spondylitis
- knee osteoarthritis
- human health
- systemic lupus erythematosus
- risk assessment
- blood brain barrier
- climate change
- smoking cessation
- combination therapy
- machine learning
- artificial intelligence
- systemic sclerosis
- postoperative pain